Current Studies

Advancing GI medical care and disease prevention

GANV is committed not only to delivering compassionate care to our patients on a daily basis, but also to remaining at the forefront of new discoveries in our field through research and education. Our physicians are continually engaged in national research projects.

We are currently enrolling patients in the following studies.

Trident Study

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease (TRIDENT)

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

VIEW MORE INFO >

Anti-MAP Therapy

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)

Purpose: The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.

VIEW MORE INFO >

Registry Study

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

VIEW MORE INFO >

Allergan Study

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.

VIEW MORE INFO >

Explore Closed Studies